Head-to-head evidence
Mayzent vs Tascenso ODT
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline
Mayzent
Marketed by Novartis
NCT03623243 · Phase 3 · completed
The study was an open-label, single-arm trial with 185 participants and no placebo or active comparator, so its findings are descriptive rather than a controlled comparison. Its primary clinical endpoint was the number of participants with treatment-emergent adverse events related to siponimod; 59 participants were reported with such an event, but no comparative significance test was applicable.
Tascenso ODT
Marketed by Cycle Pharmaceuticals Ltd. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mayzent's landscape · Tascenso ODT's landscape